Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes.

[1]  H. Drexler,et al.  Cell therapy for the treatment of coronary heart disease: a critical appraisal , 2010, Nature Reviews Cardiology.

[2]  Lei Zhang,et al.  Mesenchymal stem cells modified with stromal cell-derived factor 1α improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction , 2010, Molecules and cells.

[3]  Joshua M Hare,et al.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[4]  M. Rosen,et al.  Coupling an HCN2‐expressing cell to a myocyte creates a two‐cell pacing unit , 2009, The Journal of physiology.

[5]  J. Fehrenbacher,et al.  Proinflammatory cytokine effects on mesenchymal stem cell therapy for the ischemic heart. , 2009, The Annals of thoracic surgery.

[6]  P. Delafontaine,et al.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. , 2009, Cell stem cell.

[7]  N. Frangogiannis,et al.  The role of IL-1 in the pathogenesis of heart disease , 2009, Archivum Immunologiae et Therapiae Experimentalis.

[8]  W. Chao.  Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. , 2009, American journal of physiology. Heart and circulatory physiology.

[9]  Meijing Wang,et al.  VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. , 2008, American journal of physiology. Heart and circulatory physiology.

[10]  M. Gnecchi,et al.  Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy , 2008, Circulation research.

[11]  F. Cunha,et al.  THE ROLE OF NEUTROPHILS IN SEVERE SEPSIS , 2008, Shock.

[12]  S. Gronthos,et al.  Concise Review: Mesenchymal Stromal Cells: Potential for Cardiovascular Repair , 2008, Stem cells.

[13]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[14]  N. Rosenthal,et al.  Interleukin-10 From Transplanted Bone Marrow Mononuclear Cells Contributes to Cardiac Protection After Myocardial Infarction , 2008, Circulation research.

[15]  C. Dinarello,et al.  Cytokines link Toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. , 2008, The Annals of thoracic surgery.

[16]  Jang-Whan Bae,et al.  Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. , 2008, Journal of the American College of Cardiology.

[17]  Meijing Wang,et al.  Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. , 2008, American journal of physiology. Cell physiology.

[18]  Arjun Deb,et al.  SFRP2 Regulates Cardiomyogenic Differentiation by Inhibiting a Positive Transcriptional Autofeedback Loop of Wnt3a , 2008, Stem cells.

[19]  Meijing Wang,et al.  INTERLEUKIN 18 IN THE HEART , 2007, Shock.

[20]  C. Dinarello,et al.  The interaction between myocardial depressant factors in endotoxemic cardiac dysfunction: role of TNF-alpha in TLR4-mediated ICAM-1 expression. , 2007, Cytokine.

[21]  M. Ashraf,et al.  HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia. , 2007, Journal of molecular and cellular cardiology.

[22]  S. Humphries,et al.  A common interleukin 18 haplotype is associated with higher body mass index in subjects with diabetes and coronary heart disease. , 2007, Metabolism: clinical and experimental.

[23]  W. R. Mills,et al.  Stem cell therapy enhances electrical viability in myocardial infarction. , 2007, Journal of molecular and cellular cardiology.

[24]  M. Ashraf,et al.  In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. , 2007, Journal of molecular and cellular cardiology.

[25]  Arjun Deb,et al.  Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair , 2007, Proceedings of the National Academy of Sciences.

[26]  T. Rogers,et al.  Regulating the regulator: NF-kappaB signaling in heart. , 2006, Journal of molecular and cellular cardiology.

[27]  F. Mohr,et al.  Effects of autologous bone marrow stem cell transplantation on beta-adrenoceptor density and electrical activation pattern in a rabbit model of non-ischemic heart failure , 2006, Journal of cardiothoracic surgery.

[28]  M. Ashraf,et al.  Bone Marrow Stem Cells Prevent Left Ventricular Remodeling of Ischemic Heart Through Paracrine Signaling , 2006, Circulation research.

[29]  M. Raffeld,et al.  Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma , 2006, The Journal of experimental medicine.

[30]  P. Wernet,et al.  Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. , 2005, Journal of the American College of Cardiology.

[31]  J. Ingwall,et al.  Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells , 2005, Nature Medicine.

[32]  Smit Pc.  Myocardial repair with autologous skeletal myoblasts: a review of the clinical studies and problems , 2004 .

[33]  A. Cohen-Solal,et al.  Evidence for altered interleukin (IL)‐18 pathway in human heart failure , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  M. Ashraf,et al.  Differentiation of Bone Marrow Stromal Cells Into the Cardiac Phenotype Requires Intercellular Communication With Myocytes , 2004, Circulation.

[35]  M. Pittenger,et al.  Mesenchymal stem cells and their potential as cardiac therapeutics. , 2004, Circulation research.

[36]  Michael R Rosen,et al.  Human mesenchymal stem cells make cardiac connexins and form functional gap junctions , 2004, The Journal of physiology.

[37]  J. Ingwall,et al.  Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts , 2003, Nature Medicine.

[38]  G. Christensen,et al.  Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. , 2003, Cardiovascular research.

[39]  R. McIntyre,et al.  Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. , 2002, American journal of physiology. Heart and circulatory physiology.

[40]  I. Singh,et al.  Endotoxin stress-response in cardiomyocytes: NF-κB activation and tumor necrosis factor-α expression , 2002 .